The NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

A new approach to cancer treatment became available shortly before Jimmy Carter needed it. Now it's a pillar of care.

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

Ten years on from their approval, GlobalData reviews their market entry strategies, pricing dynamics over time, and ...

Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma. Read ...

A huge leap in fine for wrongly using mobility parks, help with childcare costs and access to Keytruda are just some of the ...

Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to ...

In it, they give the example of a cancer drug called nivolumab, which can improve outcomes for patients. In trials – during which people with different 'types' of cancer were included – the drug has ...

Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal ...

Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized phase II/III ...

One upcoming decision—on a perioperative PD-1 regimen for lung cancer—comes as the FDA considers an overhaul of trial designs in this treatment setting.